Clinical Trials

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03504644 2026-04-02

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

40 enrolled 18 charts

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03534323 2026-03-23

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

55 enrolled 14 charts

Phase 3 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03336333 2026-03-09

SEQUOIA

590 enrolled 12 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04285567 2026-03-03

CRISTALLO

166 enrolled 27 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

8 enrolled 20 charts

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

NCT03580928 2026-02-13

AVO

72 enrolled 12 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

87 enrolled 30 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05464836 2025-11-26

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Phase 2 Terminated

2 enrolled 10 charts

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02242942 2025-11-06

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

445 enrolled 22 charts 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05192889 2025-09-22

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

35 enrolled 12 charts

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03834688 2025-08-11

PrE0405

33 enrolled 15 charts

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT03872180 2025-08-06

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

23 enrolled 15 charts

Phase 2 Active not recruiting

Lymphoma, Mantle-Cell

NCT04273139 2025-07-30

Ibrutinib + Venetoclax in Untreated WM

45 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT03112174 2025-07-22

SYMPATICO

366 enrolled 45 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT02956382 2025-07-18

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

24 enrolled 18 charts

Lymphoma, Lymphoma, Follicular, Recurrence

NCT04477486 2025-07-09

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

13 enrolled 10 charts

Lymphoma, Mantle-Cell

NCT03113422 2025-05-23

PrE0403

56 enrolled 21 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

LymphoidMyeloidOther hematologic neoplasm

17 enrolled 15 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03583424 2025-05-14

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

19 enrolled 12 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT03576547 2025-05-08

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

LymphoidMyeloidOther hematologic neoplasm

9 enrolled 11 charts

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03492125 2025-04-10

A Study Of The Selective PKC-β Inhibitor MS- 553

60 enrolled 20 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04419389 2025-03-17

R/R

1 enrolled 4 charts

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Phase 1 Completed

11 enrolled 16 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02910583 2024-12-20

Captivate

323 enrolled 33 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04029688 2024-12-20

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

CNSLymphoidOther hematologic neoplasm

38 enrolled 34 charts

Neuroblastoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03136497 2024-09-23

A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 1 Terminated

10 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT04659044 2024-09-19

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Terminated

3 enrolled 11 charts

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

120 enrolled 14 charts

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04722601 2024-05-16

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

2 enrolled 7 charts

Lymphoma, Follicular

NCT03801525 2024-04-19

ULTRA-V

Phase 2/3 Terminated

277 enrolled 19 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03534180 2023-10-19

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

12 enrolled 8 charts

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT02005471 2023-10-17

MURANO

389 enrolled 35 charts 4 FDA

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02611323 2023-10-10

A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

133 enrolled 39 charts

Lymphoma, Non-Hodgkin

NCT04016805 2023-07-24

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Phase 2 Terminated

41 enrolled 4 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02756611 2023-04-10

VENICE I

258 enrolled 27 charts

Chromosome 17 deletion, Neoplasms, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02980731 2023-02-22

VENICE II

210 enrolled 36 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02141282 2022-12-19

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

127 enrolled 17 charts

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03873493 2022-12-19

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

14 enrolled 19 charts

Leukemia, Neoplasms, Recurrence, Leukemia, Prolymphocytic, T-Cell

NCT02677324 2022-05-11

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

33 enrolled 15 charts

Waldenstrom Macroglobulinemia

NCT02639910 2021-12-20

COSMOS

24 enrolled 13 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01889186 2021-12-16

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

158 enrolled 21 charts

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03135262 2021-12-07

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

29 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03045328 2021-09-29

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

22 enrolled 14 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02055820 2020-06-11

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

267 enrolled 39 charts

Lymphoma, Non-Hodgkin

NCT02187861 2019-06-05

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

163 enrolled 30 charts